Propofol is often used to induce anaesthesia for electroconvulsive therapy. Some patients who receive propofol have fits of poor quality or inadequate duration despite increasing electroconvulsive therapy doses. Sevoflurane has been reported to exhibit pro-convulsant properties in some "at-risk" patients during anaesthesia for other procedures. The purpose of this study was to perform a randomized crossover trial in patients undergoing electroconvulsive therapy, comparing the effects on seizure parameters of propofol versus sevoflurane induction. Patients were randomly allocated to receive either sevoflurane or propofol for their first treatment. In the subsequent treatment the alternative agent was used.
It is our understanding that propofol is currently the most frequently used induction agent for anaesthesia for administration of electroconvulsive therapy (ECT). Various studies have shown that despite somewhat shorter fits being recorded with propofol, there is no decrease in clinical efficacy of the fits when compared with thiopentone 1, 2 . There still remains a subset of patients who fail to fit adequately after administration of ECT. Recent information suggests that sevoflurane can be considered a proconvulsant agent in some patients 3, 4 . Our Department, after discussion with our colleagues in the Department of Psychiatry, proposed to conduct a study to determine whether patients induced with sevoflurane had longer fits than those administered propofol. The use of sevoflurane requires an inhala-tion induction which may be of benefit for patients with a potentially difficult airway or a needle-phobia. We have found it a useful and convenient method of maintaining ongoing amnesia/anaesthesia during the initial titration doses of ECT that may take several minutes. Many patients about to undergo ECT are heavy smokers; sevoflurane has been demonstrated to be suitable as an induction agent in the smoking population 5 .
A brief review of the anaesthetic literature demonstrated limited prior research on the use of sevoflurane for this clinical application. Tanaka et al 6 , investigating the haemodynamic effects of sevoflurane compared with thiopentone, demonstrated minimal haemodynamic difference between sevoflurane (at 1.7%) and thiopentone as induction agents for ECT. Ding and White 7 , in a review article on anaesthesia for ECT, refer to sevoflurane as providing adequate anaesthesia for ECT, and in particular refer to a case study where sevoflurane was used for ECT during pregnancy, with a subsequent reduction in post-ECT uterine contractions 8 .
The purpose of this randomized crossover study was to investigate the suitability of sevoflurane for induction of anaesthesia for ECT. The aim was to determine whether there was a significant difference in fit duration or quality between those patients induced with sevoflurane and those administered the intravenous agent propofol. This study did not seek to address the question of whether the choice of sevoflurane or propofol affected the clinical efficacy of ECT on long-term psychiatric outcomes.
MATERIALS AND METHODS
After obtaining Institutional Ethics and Research Committee approval for the study, we gained the written informed consent of volunteer patients commencing a treatment course of either unilateral or bilateral ECT. The patients were enrolled between 16 November 2001 and 18 November 2002. The study included both inpatients and outpatients with an American Society of Anesthesiologists Physical Status 1-3. Exclusion criteria were involuntary patient status, patients undergoing maintenance treatments, patients with known or self-declared needle or mask phobia, or patients who had a previous history of epilepsy.
Patients enrolled in the study were randomly allocated by computer-generated random numbers to receive either sevoflurane or propofol for their initial ECT session. They then subsequently underwent induction for ECT treatment using the alternative anaesthetic agent at their next session, continuing to alternate between agents at each session until their sixth session, at which time the study was terminated. After completion of the study, anaesthesia for any subsequent ECT session was induced using either agent, based on both patient preference and the attending anaesthetist's decision.
Results from the first and second ECT sessions were not analysed. These sessions usually required repeat administration of increasing ECT voltage to obtain a fit threshold. The third and fourth treatments were compared. If the fifth and sixth treatments were completed they were also compared separately, and were treated as a separate data set.
All ECT treatments were administered in a recently completed purpose-built suite that meets the Australian and New Zealand College of Anaesthetists guidelines for administration of anaesthesia for ECT. This included an anaesthetic machine, agent monitoring and agent scavenging. Upon arrival for ECT treatment, intravenous access was established in each patient. Pulse oximetry, non-invasive blood pressure, and three-lead ECG monitoring was applied to each patient. Prior to commencement of treatment, the oxygen saturation, pulse, and blood pressure of each patient was recorded. A tourniquet was placed on the contralateral arm for the purpose of fit monitoring, using the isolated forearm technique 9 . Thymatron electroencephalogram (EEG) monitoring (Thymatron™ DGx, Somatics Inc, Lake Bluff, Illinois 1994) was applied to the patient. The observer was not present whilst anaesthesia was induced. At the initial ECT session, patients allocated to receive propofol were administered 1.0 mg/kg as a bolus dose, and then a further 0.5 mg/kg if they were not adequately anaesthetized (ascertained by lack of response to verbal command to open eyes, and loss of eyelash reflex). No further propofol was administered and the total dose of propofol required was recorded and used as the induction dose at that patient's next propofol induction. Patients allocated to receive sevoflurane were administered sevoflurane 8% in oxygen 100%, until they were adequately anaesthetized (loss of response to verbal command and eyelash reflex) with the intention of ceasing sevoflurane administration just prior to commencement of ECT. At this time, the observer entered the room. Suxamethonium 0.5 mg/kg was then administered IV and ECT administered with the use of a Thymatron. Mask ventilation was continued throughout the procedure until the return of spontaneous ventilation. The inspired and expired concentrations of oxygen, carbon dioxide and inhaled anaesthetic agent (when used) were monitored throughout the period of anaesthesia. Ventilation following suxamethonium was maintained in a consistent manner in all patients in order to ensure, as was practically possible, consistent blood gases. Careful ventilation was employed to minimise interference on the EEG trace.
The seizure outcomes measured by the "blinded" observer were motor seizure duration (by use of the isolated forearm technique), EEG seizure duration, EEG morphology, and Thymatron Post Ictal Suppression Index. The ECT dose required was also recorded. The seizure duration can be taken as the time until gross motor movements cease (in a limb isolated from the effects of intravenous suxamethonium) or as recorded on an EEG. Measures of fit quality include the morphology of the EEG trace as read by a trained observer and the post-ictal suppression index, as generated by the ECT Thymatron (in particular the uniformity of the fit and hence how quickly the EEG returns to baseline).
Upon return of adequate spontaneous ventilation, patients were placed on their side and taken to recovery, receiving oxygen via Hudson mask. They were subsequently monitored with pulse oximetry and sphygmomanometry. Oxygen saturation, pulse rate and blood pressure were recorded immediately following cessation of the seizure (time 0) and at 5, 15 and 25 minutes thereafter.
Statistical Analysis
A power analysis was performed prior to the commencement of the study. A total of 15 patients were required to detect a difference of 10 seconds in seizure duration between pairs with an alpha of 0.05 and power of 95%. Comparisons of seizure duration, post-ictal suppression index scores, EEG morphology and ECT dose were made using Wilcoxon Signed Rank tests. Heart rate and blood pressure (BP) measurements were analysed using paired t-tests. The STATA 7 statistical program was used to perform the tests. The level of significance was taken as an alpha value of 0.05. For the haemodynamic data which involved multiple comparisons, the level of significance was adjusted to an alpha value of 0.01.
RESULTS
Demographic data (Table 1 ) demonstrated a mean age in enrolled patients of 57 years, and a median American Society of Anesthesiologists physical status score of 2. Thirty-two patients were enrolled in the study to allow for withdrawals. There were two withdrawals; one patient had only three treatments before withdrawing from ECT treatment, and the other was intermittently on high dose benzodiazepines resulting in absence of a fit in response to ECT administration. Two sets of data were collected on twenty-six patients. The remaining four patients had one set of data each, resulting in fifty-six patient data sets obtained.
The median motor seizure duration as observed clinically was 18.5s for propofol and 22s for sevoflurane ( Table 2 ). The median EEG duration as recorded from the Thymatron trace was 38s for propofol and 35s for sevoflurane ( Table 2 ). There was a statistically significant difference between propofol and sevoflurane in motor seizure duration, but no statistically significant difference was demonstrated in EEG seizure duration. There was a statistically significant difference between propofol and sevoflurane in the number of EEG recordings rated as excellent; sevoflurane was associated with better EEG morphology than propofol. There was a statistically significant difference in post-ictal suppression index scores, as propofol was associated with a 3.5% higher median score compared with sevoflurane. There was no difference in median ECT dose between propofol and sevoflurane ( Table 2 ).
There were statistically significant differences in pulse rate at time zero post ECT, such that sevoflurane was associated with a mean increase of 9.4 beats per minute (bpm), compared with propofol. The pulse rate differences at other times were not statistically significant. There were differences in mean blood pressure at time zero and 5 minutes post ECT such that sevoflurane was associated with increases of 9.8 and 9.4 mmHg, compared with propofol. The blood pressure differences at other times were not statistically significant.
DISCUSSION
ECT is effective in treating many psychiatric conditions. Exactly how it works or what part of the seizure is important has not been clearly defined. Currently the dose of ECT given is determined by seizure duration and quality of the fit, in addition to the patient's clinical progress.
Some patients appear to have inadequate fits after ECT. It has been suggested that these patients should be given cerebral stimulants, such as caffeine, to improve this situation 10, 11 . There is evidence that propofol reduces ECT seizure duration, while some data suggests that sevoflurane can stimulate seizures. If sevoflurane induction enhances ECT-induced seizures, then this may improve the treatment while avoiding administering other general stimulants. The successful application of sevoflurane gas induction in ECT practice would give the anaesthetist another technique that may better suit their own or a particular patient's needs.
The results of this study show that sevoflurane offers a viable alternative to propofol for providing anaesthesia for administration of ECT. This study did not attempt to demonstrate any correlation between the clinical efficacy of ECT and either treatment. To achieve this would require blinded psychiatric assessment and a randomized equivalence trial with administration of sole agents without crossover.
The clinical significance of the 3.5 s longer motor seizures observed with sevoflurane is uncertain. In contrast, EEG signal duration was slightly shorter with sevoflurane, but this was not statistically significant. Seizure duration is historically regarded as an indicator of efficacy of ECT 12 but its importance is increasingly questioned 13 . Importantly, sevoflurane did not statistically significantly decrease motor or EEG seizure duration.
EEG morphology demonstrated a statistically significant difference between the two groups. The morphology of ECT fits under sevoflurane anaesthesia was more often rated as excellent compared with propofol. The relevance of this observation is unclear.
The well known haemodynamic changes associated with ECT 7 necessitate the inclusion of haemodynamic variables in a study of induction agents and ECT. The most frequent cause of serious complications arising during ECT are autonomic or cardiac in origin. It is therefore important to demonstrate any further changes to the cardiovascular state of a patient attributable to induction agents. There were statistically significant differences in the pulse rate at time zero post-ECT, such that sevoflurane was associated with a mean increase of 9.4 beats (bpm) compared with propofol. The other times were not statistically different. There were statistically significant differences in mean blood pressure, at time zero and 5 minutes post-ECT, such that sevoflurane was associated with an increase of 9.8 and 9.4 mmHg compared with propofol.
The clinical importance of these changes would appear minimal. The mean heart rates for both groups did not exceed 85 bpm at any point and therefore might not reflect a significant degree of tachycardia. In certain patient groups (i.e. patients with known cardiac conditions such as ischaemic heart disease), it may be advisable to avoid any periods of relative hypertension or tachycardia, but the relatively small differences in both rate and pressure are unlikely to result in any striking clinical difference. In a recent review, Kato and Foex 14 affirmed the role of both sevoflurane and propofol in providing myocardial protection against ischaemic damage in patients undergoing anaesthesia with these agents.
Recently, Wajima and coworkers 15 reported their results comparing sevoflurane alone with propofol alone, and with propofol and sevoflurane, for ECT. Interestingly, they showed that in the sevoflurane alone group, the duration of the fit was significantly shorter than in the group receiving propofol alone. They also showed that blood pressure increases were greater in the sevoflurane alone group compared with the propofol alone group, but made no comments on any adverse outcome associated with this statistically significant increase in blood pressure post ECT. They did not record the duration of elevated blood pressure. In contrast, our study specifically examined this issue and showed rapid returns to near baseline levels within five minutes, and below baseline levels by 15 minutes. It appears that the elevation of blood pressure, whilst greater in the sevoflurane group, is shortlived.
The major difference in results between our study and the Wajima study is the comparison of fit duration between the sevoflurane and propofol groups. Both studies used EEG and isolated forearm techniques to determine fit duration. Our study used induction with 8% sevoflurane whilst Wajima and coworkers used 5%; our propofol dose was 1 mg/kg whilst the dose in the Wajima study was 1.5 mg/kg. Perhaps of greater impact was that of the different method of ECT administration between the two studies. We used a dose titration technique before including the results of the treatments in our study, whilst Wajima and coworkers administered 100 volts to all patients on their first three treatments. Both studies employed fit duration as a surrogate variable for fit efficacy. Neither study examined clinical outcome. We believe that because fits were over minimal threshold in both treatment groups, both anaesthetic techniques are suitable for administration of ECT, provided account is taken of the brief increases in blood pressure in both groups (greater in the sevoflurane group). Wajima and colleagues, referring to several previous studies [16] [17] [18] [19] , stated that "... studies have shown that the reduced seizure duration obtained with propofol is not associated with a reduced therapeutic effect in comparison to that of methohexitone anaesthesia".
In conclusion, the use of sevoflurane for ECT induction presents a viable alternative to propofol. Our results do not demonstrate any statistically significant difference between the use of propofol and sevoflurane that would suggest sevoflurane creates a less satisfactory outcome, in terms of ECT quality variables. Short-term statistically significant differences in haemodynamic variables might need to be considered in patients with ischaemic heart disease or poorly controlled hypertension.
